I was initially hoping to see a PR today that Brilacidin
I was initially hoping to see a PR today that Brilacidin was successful in minimizing COVID-19’s viral load. After reading today’s PR the testing that will take place next week by the RBL will be much more detailed than that. IMO if this detailed testing is successful it will immediately position Brilacidin as a Phase III treatment and probable adjuvant to a combo vaccine for COVID-19. Note that beyond the validation of Brilacidin as an effective antiviral specific to this virus, that testing will include various dose and frequency testing to maximize effectiveness while minimizing toxicity. Also note the testing to explore synergistic properties with other small molecules that have antiviral activity. This upfront testing will IMO be a guideline to rapidly deploy Brilacidin with sound science backed dose and frequency confidence.
=========================================
“that continued coronavirus (COVID-19) testing of Brilacidin, the Company’s defensin-mimetic drug candidate, is scheduled to begin the week of May 4.”
“Concurrently, the Company is prioritizing Brilacidin’s clinical development by taking steps to rapidly advance Brilacidin testing in human trials, including preparations for engaging with regulatory authorities, as the research continues into the drug’s antiviral properties.”
“Proposed further research studies to be conducted at the RBL include:
Testing Brilacidin’s direct virucidal activity on SARS-CoV-2 in human lung epithelial cells (by preincubating the novel coronavirus with Brilacidin at varying concentrations and times of incubation);
Obtaining the in vitro concentration of Brilacidin that gives half-maximal response, the EC50 value, in lung epithelial cells;
Determining impact of multiple dose exposure of Brilacidin on SARS-CoV-2 (assessing potential for achieving greater virus control without inducing toxicity);
Evaluating time-to-treatment windows as a post-exposure therapeutic (by introducing Brilacidin at 4, 8, and 16 hours post-initial infection, with virus cultures carried forward up to 48 hours);
Exploring if Brilacidin has synergistic properties with other small molecules that have antiviral activity.”
12
1
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Mitrade's New Insurance: A Safety Net? Mitrade EU is amping up its game with some fresh insurance perks that catch the eye. They're slapping on some extra insolvency protection for clients trading under their CySEC license. Now that sounds like a financial shield anyone would want. Basically, they're adding another layer to the basic regulatory protections, and without...
Continue Reading
Breaking Down Bexicaserin's Dual Action Seems like Lundbeck's playing the long game with bexicaserin, and boy, are they shaking things up at the European Epilepsy Congress. This isn't your usual sit-back-and-watch situation. They're putting bexicaserin's dual mode of action under a magnifying glass, aiming to hit both sides of the brain's seesaw by increasing inhibitory...
Continue Reading
Telit Cinterion Takes a Bold Step in U.S. Manufacturing Here's a move you don't see every day: Telit Cinterion, one of the leading players in the IoT scene, is planting its flag firmly in the good ol' U.S. of A. They're ramping up to start churning out 4G and 5G IoT modules right on American soil by October 2026. This isn't just a small-scale ambition, folks. We're...
Continue Reading
Pushing the Boundaries of Behavioral Data When a company like RealityMine posts a whopping 75% year-over-year revenue bump, you know they're not here to mess around. Enter Soumya Bijjal, a seasoned pro stepping in as their inaugural Chief Product Officer. This isn't just about adding to the C-suite boys' club; it's about locking in on a goldmine of behavioral data that's...
Continue Reading
Helping Families Put Food on the Table Out there in Utah's schoolyards, Parker Migliorini International (PMI Foods) is taking a tangible step against hunger, whipping out a $15,000 check to back the Utah Food Bank’s Mobile School Pantry initiative. This partnership kicks off in September, aligning with Hunger Action Month, a period dedicated to spotlighting food...
Continue Reading
Shell’s Strategic Play: Snagging ARC When it comes to Shell, they don't dawdle with peanuts. Snagging ARC Resources Ltd., a Canadian energy firm rooted squarely in British Columbia and Alberta, speaks volumes about their appetite for growth. They’re shelling out approximately US$16.5 billion to pull this deal off the ground. This isn't just some casual sector play; it...
Continue Reading
New Horizons in AI: Balázs Nagy Leads There's always that one name that shakes things up, and today it's Balázs Nagy. The guy's not just playing in the AI sandbox; he's leveling the whole thing up with Project NoéMI. He's the big cheese at TheNewPush LLC, beyond just a job title. Nagy’s diving headfirst into AI workforce development in a world screaming for change....
Continue Reading
Passing the Baton in BRP's Financial Helm Alright, folks, grab your coffee and listen up. There's a shakeup coming from the cold corners of Valcourt, Quebec—BRP Inc., the powersports behemoth on the TSX: DOO, has announced a changing of the guard in their finance department. Come October 1st, there's a planned power shift as Sébastien Martel steps down as CFO, passing...
Continue Reading
RMI and Moore Team Up for Strategic Evolution Let me tell ya, RMI Direct Marketing deciding to join forces with Moore’s AudienceFirst Media is a decision that’ll ripple through the data-driven waters for quite some time. They ain’t merging, mind you, but they’re definitely tying their ships together with a shared compass set on list management and brokerage...
Continue Reading
Conference Spotlight: Endoscopic Brow Lift Plastic surgeons from across the globe are gathering in Crete, Greece, for a conference that promises to shake up the aesthetic world. Among the big names is Dr. John M. Anastasatos, who'll be lifting more than just eyebrows with his presentation on the endoscopic brow lift. This isn't just another facelift spiel—no sir—this...
Continue Reading
Top 5 Most Recently Viewed Articles
SEALSQ Aids Telcos in Speeding Up eSIM Adoption SEALSQ provides a comprehensive solution that simplifies processes for eUICC manufacturers and SM-DP+/SM-DS service providers. This streamlining enables a quicker time to market through a cost-effective and simplified design approach for obtaining GSMA PKI Certificates. Progress in eSIM Technology SEALSQ Corp (NASDAQ: LAES)...
Continue Reading
Ontex's Strategic Share Buyback Program Ontex is making headlines with its ongoing program to acquire treasury shares, which marks a significant move for the company. The decision to initiate this buyback was formally disclosed in accordance with the regulations established by the Belgian government. This proactive strategy is designed to enhance shareholder value and...
Continue Reading
Rob Kole Appointed Co-Managing Partner of Choate Hall & Stewart In a pivotal move for Choate Hall & Stewart LLP, Rob Kole has officially taken the role of co-managing partner within the esteemed law firm. With a career rooted in the firm itself, Kole brings a wealth of experience and expertise, having served in numerous capacities including practice group leader and...
Continue Reading
StakingBonus Launches Comprehensive Ethereum Staking Plans StakingBonus, a prominent name in the cryptocurrency staking industry, has recently rolled out a groundbreaking Ethereum staking plan. This innovative initiative aims to cater to both retail and institutional investors who are eager to engage in Ethereum staking. As Ethereum continues to evolve, the platform...
Continue Reading
Navigating the Rise of NYMTM Stock In a remarkable turn of events, New York Mortgage Trust Inc Preferred (NASDAQ: NYMTM) stock has reached a notable milestone by hitting a 52-week high, reflected by its price point of $24.55. This impressive performance signifies not only a strong market resurgence but also highlights the growing confidence investors have in the company....
Continue Reading